BioLight Life Sciences (BioLight Life Sciences) Total Current Assets : $2.37 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is BioLight Life Sciences Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. BioLight Life Sciences's total current assets for the quarter that ended in Dec. 2023 was $2.37 Mil.

BioLight Life Sciences Total Current Assets Historical Data

The historical data trend for BioLight Life Sciences's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLight Life Sciences Total Current Assets Chart

BioLight Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

10.64

13.44

8.88

4.71

2.37

BioLight Life Sciences Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Current Assets	Get a 7-Day Free Trial															8.88	6.78	4.71	24.44	2.37

BioLight Life Sciences Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

BioLight Life Sciences's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2.258	+	0.108	+	0	+	0
	=	2.37

BioLight Life Sciences's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2.258	+	0.108	+	0	+	0
	=	2.37

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

BioLight Life Sciences (NAS:BOLT) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

BioLight Life Sciences's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.258	-	0.823	+	0.75 * 0.108	+	0.5 * 0
=	1.52

BioLight Life Sciences Total Current Assets Related Terms

Thank you for viewing the detailed overview of BioLight Life Sciences's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLight Life Sciences (BioLight Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLight Life Sciences Ltd (NAS:BOLT) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

BOLT:Israel

Address

Kiryat Atidim, Building 7, Entrance 1, 2nd Floor, Tel-Aviv, ISR, 6158101

Website

http://www.bio-light.co.il

BioLight Life Sciences Ltd is an emerging global ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.